Molecular basis of statin-associated myopathy

Christos Vaklavas, Ioannis S Chatzizisis, Anthony Ziakas, Chrysanthos Zamboulis, George D. Giannoglou

Research output: Contribution to journalReview article

83 Citations (Scopus)

Abstract

Coronary artery disease (CAD) constitutes the most common cause of morbidity and mortality in developed countries. Statins effectively reduce low-density lipoprotein cholesterol, an important risk factor for CAD and related acute coronary syndromes. They are an extensively studied group of drugs with versatile properties. Overall, they are safe and effective drugs but their myotoxic potential cannot be overlooked. In this review we focus on the pathogenesis of statins' myopathic side effects. Statins can interfere with protein modification at multiple levels. They can affect protein prenylation, an important post-translational modification of membrane bound proteins. They can also adversely affect selenoprotein synthesis, or can interfere with the biosynthesis of dolichols, which are involved in the process of protein glycosylation. Statin-induced myopathy may be also associated with mitochondrial dysfunction. Statins remain the spearhead of our armamentarium in treating atherosclerotic disease. Consistent with their versatile properties it is anticipated to see in the future their indications to expand. Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety.

Original languageEnglish (US)
Pages (from-to)18-28
Number of pages11
JournalAtherosclerosis
Volume202
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Coronary Artery Disease
Protein Prenylation
Dolichol
Selenoproteins
Post Translational Protein Processing
Acute Coronary Syndrome
Glycosylation
Developed Countries
Pharmaceutical Preparations
LDL Cholesterol
Membrane Proteins
Morbidity
Safety
Mortality

Keywords

  • Molecular biology
  • Myopathy
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Molecular basis of statin-associated myopathy. / Vaklavas, Christos; Chatzizisis, Ioannis S; Ziakas, Anthony; Zamboulis, Chrysanthos; Giannoglou, George D.

In: Atherosclerosis, Vol. 202, No. 1, 01.01.2009, p. 18-28.

Research output: Contribution to journalReview article

Vaklavas, C, Chatzizisis, IS, Ziakas, A, Zamboulis, C & Giannoglou, GD 2009, 'Molecular basis of statin-associated myopathy', Atherosclerosis, vol. 202, no. 1, pp. 18-28. https://doi.org/10.1016/j.atherosclerosis.2008.05.021
Vaklavas, Christos ; Chatzizisis, Ioannis S ; Ziakas, Anthony ; Zamboulis, Chrysanthos ; Giannoglou, George D. / Molecular basis of statin-associated myopathy. In: Atherosclerosis. 2009 ; Vol. 202, No. 1. pp. 18-28.
@article{d10110b42aeb4dd1bc5e8e563a9f1cfe,
title = "Molecular basis of statin-associated myopathy",
abstract = "Coronary artery disease (CAD) constitutes the most common cause of morbidity and mortality in developed countries. Statins effectively reduce low-density lipoprotein cholesterol, an important risk factor for CAD and related acute coronary syndromes. They are an extensively studied group of drugs with versatile properties. Overall, they are safe and effective drugs but their myotoxic potential cannot be overlooked. In this review we focus on the pathogenesis of statins' myopathic side effects. Statins can interfere with protein modification at multiple levels. They can affect protein prenylation, an important post-translational modification of membrane bound proteins. They can also adversely affect selenoprotein synthesis, or can interfere with the biosynthesis of dolichols, which are involved in the process of protein glycosylation. Statin-induced myopathy may be also associated with mitochondrial dysfunction. Statins remain the spearhead of our armamentarium in treating atherosclerotic disease. Consistent with their versatile properties it is anticipated to see in the future their indications to expand. Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety.",
keywords = "Molecular biology, Myopathy, Statins",
author = "Christos Vaklavas and Chatzizisis, {Ioannis S} and Anthony Ziakas and Chrysanthos Zamboulis and Giannoglou, {George D.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.atherosclerosis.2008.05.021",
language = "English (US)",
volume = "202",
pages = "18--28",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Molecular basis of statin-associated myopathy

AU - Vaklavas, Christos

AU - Chatzizisis, Ioannis S

AU - Ziakas, Anthony

AU - Zamboulis, Chrysanthos

AU - Giannoglou, George D.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Coronary artery disease (CAD) constitutes the most common cause of morbidity and mortality in developed countries. Statins effectively reduce low-density lipoprotein cholesterol, an important risk factor for CAD and related acute coronary syndromes. They are an extensively studied group of drugs with versatile properties. Overall, they are safe and effective drugs but their myotoxic potential cannot be overlooked. In this review we focus on the pathogenesis of statins' myopathic side effects. Statins can interfere with protein modification at multiple levels. They can affect protein prenylation, an important post-translational modification of membrane bound proteins. They can also adversely affect selenoprotein synthesis, or can interfere with the biosynthesis of dolichols, which are involved in the process of protein glycosylation. Statin-induced myopathy may be also associated with mitochondrial dysfunction. Statins remain the spearhead of our armamentarium in treating atherosclerotic disease. Consistent with their versatile properties it is anticipated to see in the future their indications to expand. Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety.

AB - Coronary artery disease (CAD) constitutes the most common cause of morbidity and mortality in developed countries. Statins effectively reduce low-density lipoprotein cholesterol, an important risk factor for CAD and related acute coronary syndromes. They are an extensively studied group of drugs with versatile properties. Overall, they are safe and effective drugs but their myotoxic potential cannot be overlooked. In this review we focus on the pathogenesis of statins' myopathic side effects. Statins can interfere with protein modification at multiple levels. They can affect protein prenylation, an important post-translational modification of membrane bound proteins. They can also adversely affect selenoprotein synthesis, or can interfere with the biosynthesis of dolichols, which are involved in the process of protein glycosylation. Statin-induced myopathy may be also associated with mitochondrial dysfunction. Statins remain the spearhead of our armamentarium in treating atherosclerotic disease. Consistent with their versatile properties it is anticipated to see in the future their indications to expand. Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety.

KW - Molecular biology

KW - Myopathy

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=57649158467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649158467&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.05.021

DO - 10.1016/j.atherosclerosis.2008.05.021

M3 - Review article

VL - 202

SP - 18

EP - 28

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -